A Case of Sepsis Caused by Cellulitis in a Patient with Rheumatoid Arthritis after Tocilizumab Treatment
Journal of Rheumatic Diseases
; : 55-60, 2016.
Article
in En
| WPRIM
| ID: wpr-215897
Responsible library:
WPRO
ABSTRACT
Tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor, is therapeutically effective in patients diagnosed with rheumatoid arthritis (RA) compared with placebo. However patients treated with tocilizumab are at increased risk of several adverse effects including anaphylaxis and serious infections that may lead to hospitalization or death. Therefore, the risks and benefits of treatment with tocilizumab should be considered carefully and close monitoring of patients for development of signs and symptoms of side effects is required during and after treatment. Here, we report on a rare case of anaphylaxis and severe sepsis caused by cellulitis in a patient with RA after tocilizumab treatment.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Arthritis, Rheumatoid
/
Cellulitis
/
Interleukin-6
/
Sepsis
/
Risk Assessment
/
Hospitalization
/
Anaphylaxis
Type of study:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Journal of Rheumatic Diseases
Year:
2016
Type:
Article